Drug Shows 10-Month Survival Improvement in Sarcoma

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.

In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma. The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. Read our conference report of this study.

 

Related Videos
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Related Content
Patients with desmoid tumors can now receive nirogacestat following the FDA’s approval of the agent.

FDA OKs Nirogacestat for Treatment of Desmoid Tumors

November 27th 2023
Article

Patients with desmoid tumors can now receive nirogacestat following the FDA’s approval of the agent.

Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.

Sarcoma Awareness Month 2023 with Brian Van Tine, MD, PhD

August 1st 2023
Podcast

Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.

Unusual Clinical Presentation of Clear Cell Sarcoma in a Young Woman

Unusual Clinical Presentation of Clear Cell Sarcoma in a Young Woman

October 12th 2023
Article

A young woman presents with painless lumps to the emergency department and is later diagnosed with clear cell carcinoma.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Oncology On-The-Go Podcast: ASCO 2023 Recap

June 19th 2023
Podcast

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Findings from a prospective study indicate that patients with undifferentiated pleomorphic sarcoma and leiomyosarcoma may present similarly to elderly patients with osteosarcoma.

Chemotherapy in RPMBS Yields Similar Survival to Osteosarcoma Population

August 31st 2023
Article

Findings from a prospective study indicate that patients with undifferentiated pleomorphic sarcoma and leiomyosarcoma may present similarly to elderly patients with osteosarcoma.

Olaparib plus temozolomide appears to prolong median progression-free survival for those with homologous recombination deficient uterine leiomyosarcoma compared with homologous recombination proficient tumors.

Olaparib Combo Provides Meaningful Benefit in Uterine Leiomyosarcoma

August 21st 2023
Article

Olaparib plus temozolomide appears to prolong median progression-free survival for those with homologous recombination deficient uterine leiomyosarcoma compared with homologous recombination proficient tumors.